Opaleye Management Inc. Keros Therapeutics, Inc. Transaction History

Opaleye Management Inc.

$411 Million
Q1 2024

A detailed history of Opaleye Management Inc. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 367,500 shares of KROS stock, worth $16.8 Million. This represents 5.92% of its overall portfolio holdings.

Number of Shares

367,500

Previous 367,500 -0.0%

Holding current value

$16.8 Million

Previous $24.3 Million -0.0%

% of portfolio

5.92%

Previous 5.98%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $412,600 - $704,800	10,000 Added 2.8%	367,500 $24.3 Million
Q4 2023 Feb 14, 2024	SELL	$27.12 - $41.05 $78,648 - $119,044	-2,900 Reduced 0.8%	357,500 $14.2 Million
Q3 2023 Nov 14, 2023	BUY	$31.57 - $43.02 $244,667 - $333,405	7,750 Added 2.2%	360,400 $11.5 Million
Q2 2023 Aug 14, 2023	BUY	$37.26 - $51.01 $4.27 Million - $5.85 Million	114,650 Added 48.17%	352,650 $14.2 Million
Q4 2022 Feb 10, 2023	SELL	$39.45 - $51.77 $3.29 Million - $4.31 Million	-83,300 Reduced 25.93%	238,000 $11.4 Million

Q3 2022 Nov 14, 2022	BUY	$27.8 - $40.12 $1.26 Million - $1.82 Million	45,300 Added 16.41%	321,300 $12.1 Million
Q2 2022 Aug 15, 2022	BUY	$26.03 - $67.04 $266,807 - $687,160	10,250 Added 3.86%	276,000 $7.63 Million
Q4 2021 Feb 14, 2022	SELL	$36.95 - $62.89 $3.21 Million - $5.46 Million	-86,750 Reduced 24.61%	265,750 $15.5 Million
Q3 2021 Nov 16, 2021	BUY	$29.27 - $43.71 $3.44 Million - $5.14 Million	117,500 Added 50.0%	352,500 $13.9 Million
Q2 2021 Aug 16, 2021	BUY	$42.4 - $70.11 $3.29 Million - $5.43 Million	77,500 Added 49.21%	235,000 $9.98 Million
Q1 2021 May 18, 2021	BUY	$54.0 - $75.28 $8.51 Million - $11.9 Million	157,500 New	157,500 $9.69 Million

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.

Account

Opaleye Management Inc. Keros Therapeutics, Inc. Transaction History